ATRX News and Press, Adhera Therapeutics Inc From 11/13/23

Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024

Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 D iabetes drug candidate Company moving forward with application to transition from OTC to NASDAQ Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) ...

Adhera Therapeutics ( OTCQB:ATRX ) appointed company director since November 5, 2021 and with 35 years experience in research, development and commercialization in multinational pharmaceutical companies, Zahed Subhan as Board Chairman and Chief Executive Officer succeedi...

Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed...

Adhera Therapeutics ( OTCQB:ATRX ) said on Tuesday the company had entered a heads of terms agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel protein complex for targeted treatment of advanced cancers. Paclitaxel is a drug approved by the U...

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreemen...

Adhera Therapeutics (OTCPK:ATRX +10.9%) is pleased to announce the appointment of Trond K. Waerness as Chairman of the Co.’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021, will be replacing Andrew Kucharchuk, who will remain CEO and Vic...

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors. Mr. Waerness...

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board. Dr. Buteau, a ...

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB ® Venture Marketplace (the ...